<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39193332</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system.</ArticleTitle><Pagination><StartPage>1392263</StartPage><MedlinePgn>1392263</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1392263</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1392263</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Sacubitril/valsartan is extensively used in heart failure; however, there are few long-term safety studies of it in a wide range of populations. The aim of this study was to evaluate sacubitril/valsartan-induced adverse events (AEs) through data mining of the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Reports in the FAERS from the third quarter of 2015 (FDA approval of sacubitril/valsartan) to the fourth quarter of 2023 were collected and analyzed. Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM) algorithms were adopted in data mining to quantify signals of sacubitril/valsartan-associated AEs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 12,001,275 reports of sacubitril/valsartan as the "primary suspected (PS)" and 99,651 AEs induced by sacubitril/valsartan were identified. More males than females reported AEs (59.95% vs. 33.31%), with the highest number of reports in the 60-70 years age group (8.11%), and most AEs occurred &lt; 7 days (14.13%) and ≥ 60 days (10.69%) after dosing. Sacubitril/valsartan-induced AE occurrence targeted 24 system organ classes (SOCs) and 294 preferred terms (PTs). Of these, 4 SOCs were strongly positive for all four algorithms, including cardiac disorders, vascular disorders, ear and labyrinth disorders, and respiratory, thoracic and mediastinal disorders. Among all PTs, consistent with the specification, hypotension (n = 10,078) had the highest number of reports, and dizziness, cough, peripheral swelling, blood potassium increased, and renal impairment were also reported in high numbers. Notably, this study also discovered a high frequency of side effects such as death, dyspnea, weight change, feeling abnormal, hearing loss, memory impairment, throat clearing, and diabetes mellitus.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study identified potential new AE signals and gained a more general understanding of the safety of sacubitril/valsartan, promoting its rational adoption in the cardiovascular system.</AbstractText><CopyrightInformation>Copyright © 2024 Wang and Liu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Xi'an International Medical Center Hospital Affiliated to Northwest University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xuna</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shaanxi Provincial People's Hospital, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FAERS database</Keyword><Keyword MajorTopicYN="N">adverse event</Keyword><Keyword MajorTopicYN="N">data mining</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">sacubitril/valsartan</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>4</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39193332</ArticleId><ArticleId IdType="pmc">PMC11347302</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1392263</ArticleId><ArticleId IdType="pii">1392263</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bate A., Lindquist M., Edwards I. R., Olsson S., Orre R., Lansner A., et al. (1998). A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315–321. 10.1007/s002280050466</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002280050466</ArticleId><ArticleId IdType="pubmed">9696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B., Nair A. P., Misra A., Scott C. Z., Mahar J. H., Fedson S. (2023). Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions. JACC Basic Transl. Sci. 8, 88–105. 10.1016/j.jacbts.2022.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2022.05.010</ArticleId><ArticleId IdType="pmc">PMC9911324</ArticleId><ArticleId IdType="pubmed">36777165</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Ding L., Fu F., Xiao J. (2023). Updated insights on dementia-related risk of sacubitril/valsartan: a real-world pharmacovigilance analysis. CNS Neurosci. Ther. 29, 2548–2554. 10.1111/cns.14195</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.14195</ArticleId><ArticleId IdType="pmc">PMC10401082</ArticleId><ArticleId IdType="pubmed">36971193</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Elia E., Iacovoni A., Vaduganathan M., Lorini F. L., Perlini S., Senni M. (2017). Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur. J. Heart Fail 19, 710–717. 10.1002/ejhf.799</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.799</ArticleId><ArticleId IdType="pubmed">28326642</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A. S., Solomon S., Claggett B., McMurray J. J. V., Rouleau J., Swedberg K., et al. (2016). Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial. Circ. Heart Fail 9, e002735. 10.1161/CIRCHEARTFAILURE.115.002735</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.115.002735</ArticleId><ArticleId IdType="pubmed">27296397</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominici F. P., Burghi V., Muñoz M. C., Giani J. F. (2014). Modulation of the action of insulin by angiotensin-(1-7). Clin. Sci. (Lond) 126, 613–630. 10.1042/CS20130333</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20130333</ArticleId><ArticleId IdType="pubmed">24450744</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumouchel W. (1999). Bayesian data mining in large frequency tables, with an application to the fda spontaneous reporting system. Am. Statistician 53, 177–190. 10.1080/00031305.1999.10474456</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00031305.1999.10474456</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans S. J., Waller P. C., Davis S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10, 483–486. 10.1002/pds.677</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.677</ArticleId><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Ruiz I. (2017). Diabetes: sacubitril/valsartan improves glycaemic control. Nat. Rev. Cardiol. 14, 252. 10.1038/nrcardio.2017.44</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2017.44</ArticleId><ArticleId IdType="pubmed">28361973</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Ruiz I. (2020). Dissecting the benefits of sacubitril-valsartan for heart failure. Nat. Rev. Cardiol. 17, 71. 10.1038/s41569-019-0322-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-019-0322-y</ArticleId><ArticleId IdType="pubmed">31792406</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti M., Antonazzo I. C., Diemberger I., De Ponti F., Raschi E. (2021). Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur. J. Prev. Cardiol. 28, 983–989. 10.1177/2047487320915663</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487320915663</ArticleId><ArticleId IdType="pubmed">34402868</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene S. J., Choi S., Lippmann S. J., Mentz R. J., Greiner M. A., Hardy N. C., et al. (2021). Clinical effectiveness of sacubitril/valsartan among patients hospitalized for heart failure with reduced ejection fraction. J. Am. Heart Assoc. 10, e021459. 10.1161/JAHA.121.021459</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.021459</ArticleId><ArticleId IdType="pmc">PMC8475054</ArticleId><ArticleId IdType="pubmed">34350772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Zhou L., Shen Y., Zhou Q., Ji Y., Zhu H. (2024). Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J. Affect. Disord. 346, 223–229. 10.1016/j.jad.2023.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2023.11.025</ArticleId><ArticleId IdType="pubmed">37956832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. S., Brar S., D’Albo N., Dey A., Shah S., Ganatra S., et al. (2022). Five years of sacubitril/valsartan-a safety analysis of randomized clinical trials and real-world pharmacovigilance. Cardiovasc Drugs Ther. 36, 915–924. 10.1007/s10557-021-07210-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-021-07210-1</ArticleId><ArticleId IdType="pubmed">34125356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam C. S. P., Arnott C., Beale A. L., Chandramouli C., Hilfiker-Kleiner D., Kaye D. M., et al. (2019). Sex differences in heart failure. Eur. Heart J. 40, 3859–3868c. 10.1093/eurheartj/ehz835</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz835</ArticleId><ArticleId IdType="pubmed">31800034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerman T. T., Greenberg N., Fishman B., Goldman A., Talmor-Barkan Y., Bauer M., et al. (2024). The real-world safety of sacubitril/valsartan among older adults (≥75): a pharmacovigilance study from the FDA data. Int. J. Cardiol. 397, 131613. 10.1016/j.ijcard.2023.131613</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2023.131613</ArticleId><ArticleId IdType="pubmed">38030039</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S. S., Aday A. W., Almarzooq Z. I., Anderson C. A. M., Arora P., Avery C. L., et al. (2024). 2024 heart disease and stroke statistics: a report of us and global data from the American heart association. Circulation 149, e347–e913. 10.1161/CIR.0000000000001209</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001209</ArticleId><ArticleId IdType="pubmed">38264914</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray J. J. V., Packer M., Desai A. S., Gong J., Lefkowitz M. P., Rizkala A. R., et al. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004. 10.1056/NEJMoa1409077</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1409077</ArticleId><ArticleId IdType="pubmed">25176015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P., Voors A. A., Anker S. D., Bueno H., Cleland J. G. F., Coats A. J. S., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail 18, 891–975. 10.1002/ejhf.592</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.592</ArticleId><ArticleId IdType="pubmed">27207191</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas García S., Álvarez-García J. (2024). Sacubitril/valsartan: where mechanism meets evidence-based medicine. Eur. J. Heart Fail 26, 127–129. 10.1002/ejhf.3100</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.3100</ArticleId><ArticleId IdType="pubmed">38037688</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman K. J., Lanes S., Sacks S. T. (2004). The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 13, 519–523. 10.1002/pds.1001</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1001</ArticleId><ArticleId IdType="pubmed">15317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Seferovic J. P., Claggett B., Seidelmann S. B., Seely E. W., Packer M., Zile M. R., et al. (2017). Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 5, 333–340. 10.1016/S2213-8587(17)30087-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(17)30087-6</ArticleId><ArticleId IdType="pmc">PMC5534167</ArticleId><ArticleId IdType="pubmed">28330649</ArticleId></ArticleIdList></Reference><Reference><Citation>Senni M., McMurray J. J. V., Wachter R., McIntyre H. F., Reyes A., Majercak I., et al. (2016). Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur. J. Heart Fail 18, 1193–1202. 10.1002/ejhf.548</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.548</ArticleId><ArticleId IdType="pmc">PMC5084812</ArticleId><ArticleId IdType="pubmed">27170530</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J. S. S., Burrell L. M., Cherif M., Squire I. B., Clark A. L., Lang C. C. (2017). Sacubitril/valsartan: beyond natriuretic peptides. Heart 103, 1569–1577. 10.1136/heartjnl-2017-311295</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2017-311295</ArticleId><ArticleId IdType="pubmed">28689178</ArticleId></ArticleIdList></Reference><Reference><Citation>Voordes G. H. D., Heerspink H. J. L., Ter Maaten J. M. (2022). The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function. Eur. J. Heart Fail 24, 804–806. 10.1002/ejhf.2501</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2501</ArticleId><ArticleId IdType="pubmed">35415946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware L. B., Matthay M. A. (2005). Clinical practice. Acute pulmonary edema. N. Engl. J. Med. 353, 2788–2796. 10.1056/NEJMcp052699</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp052699</ArticleId><ArticleId IdType="pubmed">16382065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>